{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T21:20:11Z","timestamp":1773436811198,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1007\/s11882-006-0063-y","type":"journal-article","created":{"date-parts":[[2007,7,4]],"date-time":"2007-07-04T19:41:35Z","timestamp":1183578095000},"page":"299-305","source":"Crossref","is-referenced-by-count":30,"title":["Ocular toxicity of systemic asthma and allergy treatments"],"prefix":"10.1007","volume":"6","author":[{"given":"Leonard","family":"Bielory","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"63_CR1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0091-6749(03)01859-1","volume":"112","author":"DB Allen","year":"2003","unstructured":"Allen DB, Bielory L, Derendorf H, et al.: Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003, 112:S1-S40. Provides a multiorgan overview of the effects of steroids and considers the future development of \u201csoft\u201d steroids with a lower clinical adverse profile.","journal-title":"J Allergy Clin Immunol"},{"key":"63_CR2","first-page":"117","volume":"16","author":"GD Kewley","year":"1980","unstructured":"Kewley GD: Possible association between beclomethasone diproprionate aerosol and cataracts. Aust Paediatr J 1980, 16:117\u2013118.","journal-title":"Aust Paediatr J"},{"key":"63_CR3","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/jama.1960.63030020005014","volume":"174","author":"R Black","year":"1960","unstructured":"Black R, Oglesby R, von Sallmann L, Bunim J: Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA 1960, 174:150\u2013171.","journal-title":"JAMA"},{"key":"63_CR4","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1542\/peds.73.5.626","volume":"73","author":"RG Bhagat","year":"1984","unstructured":"Bhagat RG, Chai H: Development of posterior subcapsular cataracts in asthmatic children. Pediatrics 1984, 73:626\u2013630.","journal-title":"Pediatrics"},{"key":"63_CR5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0091-6749(79)90210-0","volume":"63","author":"A Rooklin","year":"1979","unstructured":"Rooklin A, Lampert S, Jaeger E, et al.: Posterior subcapsular cataracts in steroid requiring asthmatic children. J Allergy Clin Immunol 1979, 63:383\u2013386.","journal-title":"J Allergy Clin Immunol"},{"key":"63_CR6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0039-6257(86)90077-9","volume":"31","author":"R Urban","year":"1986","unstructured":"Urban R, Cotlier E: Corticosteroid induced cataracts. Surv Ophthalmol 1986, 31:102\u2013110.","journal-title":"Surv Ophthalmol"},{"key":"63_CR7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0002-9394(77)90328-2","volume":"84","author":"AR Forman","year":"1977","unstructured":"Forman AR, Loreto JA, Tina LU: Reversibility of corticosteroid- associated cataracts in children with the nephrotic syndrome. Am J Ophthalmol 1977, 84:75\u201378.","journal-title":"Am J Ophthalmol"},{"key":"63_CR8","first-page":"41","volume":"66","author":"R Oglesby","year":"1961","unstructured":"Oglesby R, Black R, von Sallmann L, Bunim J: Cataracts in patients with rheumatic diseases treated with corticosteroids. Arch Ophthalmol 1961, 66:41\u201346.","journal-title":"Arch Ophthalmol"},{"key":"63_CR9","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/0091-6749(87)90002-9","volume":"80","author":"E Nassif","year":"1987","unstructured":"Nassif E, Weinberger M, Sherman B, Brown K: Extrapulmonary effects of maintenance corticosteroid therapy with alternate-day prednisone and inhaled beclomethasone in children with chronic asthma. J Allergy Clin Immunol 1987, 80:518\u2013529.","journal-title":"J Allergy Clin Immunol"},{"key":"63_CR10","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/0091-6749(93)90263-F","volume":"91","author":"JH Toogood","year":"1993","unstructured":"Toogood JH, Markov AE, Baskerville J, Dyson C: Association of ocular cataracts with inhaled and oral steroid therapy during long-term treatment of asthma. J Allergy Clin Immunol 1993, 91:571\u2013579.","journal-title":"J Allergy Clin Immunol"},{"key":"63_CR11","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/0140-6736(93)91541-S","volume":"342","author":"FE Simons","year":"1993","unstructured":"Simons FE, Persaud MP, Gillespie CA, et al.: Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids. Lancet 1993, 342:776\u2013778.","journal-title":"Lancet"},{"key":"63_CR12","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/thx.49.12.1185","volume":"49","author":"G Russell","year":"1994","unstructured":"Russell G: Inhaled corticosteroid therapy in children: an assessment of the potential for side effects. Thorax 1994, 49:1185\u20131188.","journal-title":"Thorax"},{"key":"63_CR13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJM199707033370102","volume":"337","author":"R Cumming","year":"1997","unstructured":"Cumming R, Mitchell P, Leeder S: Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997, 337:8\u201314.","journal-title":"N Engl J Med"},{"key":"63_CR14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/jama.280.6.539","volume":"280","author":"E Garbe","year":"1998","unstructured":"Garbe E, Suissa S, LeLorier J:. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998, 280:539\u2013543.","journal-title":"JAMA"},{"key":"63_CR15","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0002-9343(99)80404-5","volume":"98","author":"NA Hanania","year":"1995","unstructured":"Hanania NA, Chapman KR, Kesten S: Adverse effects of inhaled corticosteroids. Am J Med 1995, 98:196\u2013208.","journal-title":"Am J Med"},{"issue":"Suppl B","key":"63_CR16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0954-6111(98)90436-X","volume":"92","author":"RG Dluhy","year":"1998","unstructured":"Dluhy RG: Effect of inhaled beclomethasone dipropionate and budesonide on adrenal function, skin changes and cataract formation. Respir Med 1998, 92(Suppl B):15\u201323.","journal-title":"Respir Med"},{"key":"63_CR17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1183\/09031936.98.12010130","volume":"12","author":"L Agertoft","year":"1998","unstructured":"Agertoft L, Larsen FE, Pedersen S: Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide. Eur Respir J 1998, 12:130\u2013135.","journal-title":"Eur Respir J"},{"key":"63_CR18","doi-asserted-by":"crossref","unstructured":"Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 2000, 343:1054\u20131063.","DOI":"10.1056\/NEJM200010123431501"},{"key":"63_CR19","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1046\/j.1365-2222.2003.01689.x","volume":"33","author":"C Moller","year":"2003","unstructured":"Moller C, Ahlstrom H, Henricson KA, et al.: Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clin Exp Allergy 2003, 33:816\u2013822.","journal-title":"Clin Exp Allergy"},{"key":"63_CR20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00001648-200103000-00016","volume":"12","author":"SS Jick","year":"2001","unstructured":"Jick SS, Vasilakis-Scaramozza C, Maier WC: The risk of cataract among users of inhaled steroids. Epidemiology 2001, 12:229\u2013234.","journal-title":"Epidemiology"},{"key":"63_CR21","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1542\/peds.113.2.e87","volume":"113","author":"H Bisgaard","year":"2004","unstructured":"Bisgaard H, Allen D, Milanowski J, et al.: Twelve-month safety and efficacy of inhaled.uticasone propionate in children aged 1 to 3 years with recurrent wheezing. Pediatrics 2004, 113:e87-e94.","journal-title":"Pediatrics"},{"key":"63_CR22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1081-1206(10)61285-9","volume":"94","author":"AL Sheffer","year":"2005","unstructured":"Sheffer AL, Silverman M, Woolcock AJ, et al.: Long-term safety of once-daily budesonide in patients with earlyonset mild persistent asthma: results of the Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) study. Ann Allergy Asthma Immunol 2005, 94:48\u201354.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"63_CR23","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/00002512-199915060-00004","volume":"15","author":"RC Tripathi","year":"1999","unstructured":"Tripathi RC, Parapuram SK, Tripathi BJ, et al.: Corticosteroids and glaucoma risk. Drugs Aging 1999, 15:439\u2013450.","journal-title":"Drugs Aging"},{"key":"63_CR24","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1167\/iovs.05-0571","volume":"46","author":"X Zhang","year":"2005","unstructured":"Zhang X, Clark AF, Yorio T: Regulation of glucocorticoid responsiveness in glaucomatous trabecular meshwork cells by glucocorticoid receptor-beta. Invest Ophthalmol Vis Sci 2005, 46:4607\u20134616.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"63_CR25","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1167\/iovs.02-1318","volume":"44","author":"J Stokes","year":"2003","unstructured":"Stokes J, Walker BR, Campbell JC, et al.: Altered peripheral sensitivity to glucocorticoids in primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2003, 44:5163\u20135167.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"63_CR26","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1056\/NEJM199312093292420","volume":"329","author":"EB Dreyer","year":"1993","unstructured":"Dreyer EB: Inhaled steroid use and glaucoma. N Engl J Med 1993, 329:1822.","journal-title":"N Engl J Med"},{"key":"63_CR27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0161-6420(95)31039-1","volume":"102","author":"I Opatowsky","year":"1995","unstructured":"Opatowsky I, Feldman RM, Gross R, Feldman ST: Intraocular pressure elevation associated with inhalation and nasal corticosteroids. Ophthalmology 1995, 102:177\u2013179.","journal-title":"Ophthalmology"},{"key":"63_CR28","first-page":"97","volume":"280","author":"M Desnoeck","year":"2001","unstructured":"Desnoeck M, Casteels I, Casteels K: Intraocular pressure elevation in a child due to the use of inhalation steroids\u2014 a case report. Bull Soc Belge Ophtalmol 2001, 280:97\u2013100.","journal-title":"Bull Soc Belge Ophtalmol"},{"key":"63_CR29","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-1999-9033","volume":"53","author":"J Hartung","year":"1999","unstructured":"Hartung J, Knapp G: [A re-analysis of the Blue Mountain eye study on the risk of cataracts from inhaled corticosteroids. A contribution to objectifying the discussion]. Pneumologie 1999, 53:411\u2013416.","journal-title":"Pneumologie"},{"key":"63_CR30","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.1997.03540330044033","volume":"277","author":"E Garbe","year":"1997","unstructured":"Garbe E, LeLorier J, Boivin JF, Suissa S: Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997, 277:722\u2013727.","journal-title":"JAMA"},{"key":"63_CR31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3928\/01913913-20050101-03","volume":"42","author":"AH Behbehani","year":"2005","unstructured":"Behbehani AH, Owayed AF, Hijazi ZM, et al.: Cataract and ocular hypertension in children on inhaled corticosteroid therapy. J Pediatr Ophthalmol Strabismus 2005, 42:23\u201327.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"63_CR32","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S1081-1206(10)62545-8","volume":"85","author":"MS Duh","year":"2000","unstructured":"Duh MS, Walker AM, Lindmark B, Laties AM: Association between intraocular pressure and budesonide inhalation therapy in asthmatic patients. Ann Allergy Asthma Immunol 2000, 85:356\u2013361.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"63_CR33","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1067\/mai.2001.115567","volume":"108","author":"J Dibildox","year":"2001","unstructured":"Dibildox J:. Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: results of recent clinical trials. J Allergy Clin Immunol 2001, 108(1 Suppl):S54-S58.","journal-title":"J Allergy Clin Immunol"},{"key":"63_CR34","first-page":"469","volume":"9","author":"RC Tripathi","year":"1992","unstructured":"Tripathi RC, Kipp MA, Tripathi BJ, et al.: Ocular toxicity of prednisone in pediatric patients with inflammatory bowel disease. Lens Eye Toxic Res 1992, 9:469\u2013482.","journal-title":"Lens Eye Toxic Res"},{"key":"63_CR35","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jaci.2005.07.031","volume":"116","author":"CM Bui","year":"2005","unstructured":"Bui CM, Chen H, Shyr Y, Joos KM: Discontinuing nasal steroids might lower intraocular pressure in glaucoma. J Allergy Clin Immunol 2005, 116:1042\u20131047. This study demonstrated the effect of discontinuing nasal steroid sprays on intraocular pressure (intraocular pressure) in patients with glaucoma that resulted in a significant reduction (4 mm) in IOP. Nasal steroids might contribute to IOP increase, and inquiry as to whether a patient has glaucoma before medication initiation is warranted.","journal-title":"J Allergy Clin Immunol"},{"key":"63_CR36","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1081-1206(10)61155-6","volume":"95","author":"W Berger","year":"2005","unstructured":"Berger W, Abelson MB, Gomes PJ, et al.: Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy. Ann Allergy Asthma Immunol 2005, 95:361\u2013371.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"63_CR37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003495-200565020-00004","volume":"65","author":"L Bielory","year":"2005","unstructured":"Bielory L, Lien KW, Bigelsen S: Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005, 65:215\u2013228.","journal-title":"Drugs"},{"key":"63_CR38","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/01.all.0000183113.63311.11","volume":"5","author":"L Bielory","year":"2005","unstructured":"Bielory L, Ghafoor S: Histamine receptors and the conjunctiva. Curr Opin Allergy Clin Immunol 2005, 5:437\u2013440. The effect of histamine on conjunctival H1 receptors appears to be the primary target for ocular allergy treatment, as it is primarily involved in ocular pruritus. Oral and topical antihistamines with multiple histamine receptor binding activities may provide an improved treatment paradigm for the various signs and symptoms of ocular allergy. The review also identifies histamine H1, H2, and H3 receptor affinities of the various commonly used antihistamines.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"63_CR39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF00154706","volume":"56","author":"L Thorig","year":"1983","unstructured":"Thorig L, Halperin M, van Haeringen NJ: The fine-thread method: lacrimation test for measuring ocular sideeffects of drugs in the rat. Doc Ophthalmol 1983, 56:35\u201339.","journal-title":"Doc Ophthalmol"},{"key":"63_CR40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF00153632","volume":"58","author":"L Thorig","year":"1984","unstructured":"Thorig L, Halperin M, van Haeringen NJ: Cotton-thread tear test: an experimental study for testing drugs suspected of side effects on lacrimation. Doc Ophthalmol 1984, 58:307\u2013315.","journal-title":"Doc Ophthalmol"},{"key":"63_CR41","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1177\/030006059202000507","volume":"20","author":"F Horak","year":"1992","unstructured":"Horak F, Jager S, Berger U: Onset and duration of the effects of three antihistamines in current use\u2014astemizole, loratadine and terfenadine forte\u2014studied during prolonged, controlled allergen challenges in volunteers. J Int Med Res 1992, 20:422\u2013434.","journal-title":"J Int Med Res"},{"key":"63_CR42","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/978-1-4615-0717-8_47","volume":"506","author":"D Welch","year":"2002","unstructured":"Welch D, Ousler GW 3rd, Nally LA, et al.: Ocular drying associated with oral antihistamines (loratadine) in the normal population\u2014an evaluation of exaggerated dose effect. Adv Exp Med Biol 2002, 506(Pt B):1051\u20131055.","journal-title":"Adv Exp Med Biol"},{"key":"63_CR43","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1081-1206(10)61413-5","volume":"93","author":"GW Ousler","year":"2004","unstructured":"Ousler GW, Wilcox KA, Gupta G, Abelson MB: An evaluation of the ocular drying effects of 2 systemic antihistamines: loratadine and cetirizine hydrochloride. Ann Allergy Asthma Immunol 2004, 93:460\u2013464. Oral antihistamines, such as loratadine and cetirizine hydrochloride, have proven efficacious in the control of many allergic conditions; however, these agents have also been associated with inducing signs and symptoms associated with ocular dryness, including increased corneal and conjunctival staining, decreased tear-.lm breakup time, and increased ocular discomfort in healthy individuals.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"63_CR44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2210-5-13","volume":"5","author":"G Howell","year":"2005","unstructured":"Howell G 3rd, West L, Jenkins C, et al.: In vivo antimuscarinic actions of the third generation antihistaminergic agent, desloratadine. BMC Pharmacol 2005, 5:13.","journal-title":"BMC Pharmacol"},{"key":"63_CR45","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2210-5-8","volume":"5","author":"H Liu","year":"2005","unstructured":"Liu H, Farley JM: Effects of.rst and second generation antihistamines on muscarinic induced mucus gland cell ion transport. BMC Pharmacol 2005, 5:8.","journal-title":"BMC Pharmacol"},{"key":"63_CR46","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2165\/00003088-200241070-00006","volume":"41","author":"L Grumetto","year":"2002","unstructured":"Grumetto L, Cennamo G, Del Prete A, et al.: Pharmacokinetics of cetirizine in tear.uid after a single oral dose. Clin Pharmacokinet 2002, 41:525\u2013531.","journal-title":"Clin Pharmacokinet"},{"key":"63_CR47","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1542\/peds.92.1.64","volume":"92","author":"DG Tinkelman","year":"1993","unstructured":"Tinkelman DG, Reed CE, Nelson HS, Offord KP: Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 1993, 92:64\u201377.","journal-title":"Pediatrics"},{"key":"63_CR48","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1056\/NEJM199312023292305","volume":"329","author":"B Volovitz","year":"1993","unstructured":"Volovitz B, Amir J, Malik H, et al.: Growth and pituitary-adrenal function in children with severe asthma treated with inhaled budesonide. N Engl J Med 1993, 329:1703\u20131708.","journal-title":"N Engl J Med"},{"key":"63_CR49","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1177\/014556139807701012","volume":"77","author":"F Ozturk","year":"1998","unstructured":"Ozturk F, Yuceturk AV, Kurt E, et al.: Evaluation of intraocular pressure and cataract formation following the long-term use of nasal corticosteroids. Ear Nose Throat J 1998, 77:846\u2013848, 850-841.","journal-title":"Ear Nose Throat J"},{"key":"63_CR50","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/00002018-199920010-00007","volume":"20","author":"RG Cumming","year":"1999","unstructured":"Cumming RG, Mitchell P: Inhaled corticosteroids and cataract: prevalence, prevention and management. Drug Saf 1999, 20:77\u201384.","journal-title":"Drug Saf"},{"issue":"3","key":"63_CR51","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0022-3476(98)70003-4","volume":"132","author":"JS Wagener","year":"1998","unstructured":"Wagener JS, Wojtczak HA: Inhaled steroids in children: risks versus rewards. J Pediatr 1998, 132(3 Pt 1):381\u2013383.","journal-title":"J Pediatr"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-006-0063-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11882-006-0063-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-006-0063-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T21:19:08Z","timestamp":1683926348000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11882-006-0063-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["63"],"URL":"https:\/\/doi.org\/10.1007\/s11882-006-0063-y","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}